Qualys has broadened its global mROC program by partnering with key technology firms like Claroty, Lookout, and Okta to integrate risk data from mobile, IoT/OT, and identity attack surfaces into its Enterprise TruRisk Management platform. This unified approach helps organizations gain a comprehensive view of cyber risks, prioritize vulnerabilities efficiently, and respond faster amid rising AI-driven threats. The expansion includes new partner roles to support customers in adopting Risk Operations Centers, enhancing defense against rapidly evolving AI-discovered vulnerabilities. This move addresses the challenge of fragmented security tools and unmeasured risks in emerging tech areas, enabling better risk management and reporting for CISOs and boards.
Qualys expanding its global mROC alliance offers context for technology sector investors. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 09, 2026 19:42 WIB: Out of 150 priced US tech stocks, 100 rose and 41 fell. Notable movers include CIFR at USD 6.33 with a -3.36% change, SMCI at USD 27.86 with a -3.13% change, and STM at USD 43.02 with a +3.12% change.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
